Article
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Dec 2023
Damodaran S, O'Sullivan C C, Elkhanany A, Anderson I C, Barve M, Blau S, Cherian M A, Peguero J A, Goetz M P, Plourde P V, Portman D J, Moore H C F
Abstract excerpt
BACKGROUND: Acquired ESR1 mutations in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) drive treatment resistance and tumor progression; new treatment strategies are needed. Lasofoxifene, a next-generation, oral, endocrine therapy and tissue-specific ER antagonist, provided preclinical antitumor activity, alone or combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in ESR1-mutated mBC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.